All In Biotech

Drug Trial Radar · NCT00004984

The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)

Last checked: Nov 20, 2026Latest source record: Apr 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 711 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

711

Actual

Start

Feb 1994

Primary completion

Jun 2003

Study completion Jun 2003

Sponsor

Sponsor type
NIH
Collaborators
National Center for Research Resources (NCRR); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Minority Health and Health Disparities (NIMHD); Office of Research on Women's Health (ORWH)
First posted
Mar 14, 2000

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Diabetes Prevention Trial of Type 1 (DPT-1) was a multicenter randomized, controlled clinical trial designed to determine whether it is possible to delay or prevent the clinical onset of type 1 diabetes through daily doses of insulin in individuals determined to be at risk for the disease. Subjects were recruited from study clinics and through media campaigns.First-degree relatives, 3 to 45 years of age, and second-degree relatives, 3 to 20 years of age, of patients with diabetes were screened for islet-cell antibodies. Those individuals found to be at high risk of diabetes were randomized to receive either close observation or low-dose parenteral insulin. Those individuals found to be at intermediate risk of diabetes are randomized to receive insulin orally or to receive placebo. Patients were followed for up to six years.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

  • Parenteral InsulinDrug

    Subcutaneous injections of recombinant human ultralente insulin in the morning and in the evening; the initial dose for each injection was 0.125 U per kilogram of body weight.

  • Close ObservationOther

    Study visits every 6 months including an oral glucose tolerance test

  • Oral InsulinDrug

    Capsules oral insulin, 7.5 mg of recombinant human insulin crystals

  • PlaceboDrug

    Placebo for oral insulin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Type 1 Diabetes Per YearTime frame: Glucose tolerance is measured every 6 months for up to 6 years

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Childrens Hospital of Los Angeles, Division of Endocrinology

    Los Angeles, California

  • University of California-San Francisco, Milberry Union East RM 405, 500 Parnassus Ave Box 0136

    San Francisco, California

  • Stanford University

    Stanford, California

  • University of Colorado Barbara Davis Center for Childhood Diabetes

    Denver, Colorado

  • University of Florida Diabetes Research Center

    Gainesville, Florida

  • DPT-1 Operations Coordinating Center

    Miami, Florida

  • University of Miami School of Medicine, Jackson Medical Tower

    Miami, Florida

  • Indiana University, James Whitcomb Riley Hospital for Children, 702 Barnhill Dr, Ste 5960

    Indianapolis, Indiana

  • Joslin Diabetes Center

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • Naomi Berrie Diabetes Center, Columbia University, 1150 St. Nicholas Ave

    New York, New York

  • Children's Hospital of Pittsburgh, Dept/Pediatric Endocrinology, 3705 5th Ave

    Pittsburgh, Pennsylvania

  • University of Texas, Children's Medical Center, 6300 Harry Hines Ste 1200

    Dallas, Texas

  • Virginia Mason Research Center, 1201 Ninth Avenue

    Seattle, Washington

  • Hospital for Sick Children, Division of Endocrinology, 555 University Ave, Rm 5110

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.